Atea Completes Enrollment in C-BEYOND Hepatitis C Trial: Mid-2026 Data Expected
ByAinvest
Tuesday, Dec 23, 2025 2:40 am ET1min read
AVIR--
Atea Pharmaceuticals has completed enrollment in its Phase 3 trial, C-BEYOND, for its hepatitis C treatment. The trial compares the company's Bemnifosbuvir and Ruzasvir regimen to a standard of care. Topline results are expected in mid-2026, and the company has sufficient cash to fund its ongoing clinical programs. The trial is significant as it is the first to directly compare investigational direct-acting antivirals against established regimens.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet